Literature DB >> 26272533

Predictive markers, including total lesion glycolysis, for the response of lymph node(s) metastasis from head and neck squamous cell carcinoma treated by chemoradiotherapy.

Goshi Nishimura1, Masanori Komatsu2, Masaharu Hata3, Kenichiro Yabuki2, Takahide Taguchi2, Masahiro Takahashi2, Osamu Shiono2, Daisuke Sano2, Yasuhiro Arai2, Hideaki Takahashi2, Yoshihiro Chiba2, Nobuhiko Oridate2.   

Abstract

BACKGROUND: Chemoradiotherapy (CRT) is used to treat cervical lymph node(s) metastatic head and neck cancer patients. Evaluation and treatment of lymph node(s) after CRT is important to improve the prognosis.
METHODS: Prior to CRT, we determined the TNM stage by visual and imaging examinations. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated from the results of fluorodeoxyglucose-positron emission tomography (FDG-PET). After CRT, the patients were divided in two groups-complete response (CR) and non-CR-and their responses were compared with the clinical characteristics.
RESULTS: T4, N2b, N2c and TLG2.5 ≥ 18.8 were statistically significant predictive indices before CRT. The odds ratio, 95 % confidence interval and p value were, respectively-T4: 2.73, 1.15-6.51, 0.0230; N2b: 6.96, 1.50-32.3, 0.0132; N2c: 11.80, 2.37-58.50, 0.00258; and TLG2.5 ≥ 18.8: 6.25, 2.17-18.00, 0.000672.
CONCLUSIONS: TLG was found to be a good predictive factor for metastatic lymph node(s) prior to CRT treatment. After CRT treatment, FDG-PET was found to be highly specific and useful for negative screening.

Entities:  

Keywords:  Chemoradiotherapy; Head and neck squamous cell carcinoma; Metastatic lymph node; Predictive factor; Total lesion glycolysis

Mesh:

Substances:

Year:  2015        PMID: 26272533     DOI: 10.1007/s10147-015-0890-8

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  27 in total

1.  Treatment evaluation of metastatic lymph nodes after concurrent chemoradiotherapy in patients with head and neck squamous cell carcinoma.

Authors:  Goshi Nishimura; Hideki Matsuda; Takahide Taguchi; Masahiro Takahashi; Masanori Komatsu; Daisuke Sano; Naoko Sakuma; Yasuhiro Arai; Hideaki Takahashi
Journal:  Anticancer Res       Date:  2012-02       Impact factor: 2.480

2.  Combined radiotherapy and chemotherapy with carboplatin and UFT for head and neck squamous cell carcinoma.

Authors:  Takahide Taguchi; Yoichi Ikeda; Yasukazu Mikami; Satoshi Kawai; Yasuhiro Arai; Idumi Mochimatsu; Mamoru Tsukuda
Journal:  Anticancer Res       Date:  2003 Jan-Feb       Impact factor: 2.480

3.  Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx.

Authors:  Takahide Taguchi; Mamoru Tsukuda; Yasukazu Mikami; Hideki Matsuda; Choichi Horiuchi; Takafumi Yoshida; Goshi Nishimura; Jun-Ichi Ishitoya; Hideaki Katori
Journal:  Acta Otolaryngol       Date:  2006-04       Impact factor: 1.494

4.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.

Authors:  Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg
Journal:  Clin Positron Imaging       Date:  1999-05

5.  Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study.

Authors:  George Fountzilas; Elisabeta Ciuleanu; Urania Dafni; George Plataniotis; Anna Kalogera-Fountzila; Epaminontas Samantas; Eleni Athanassiou; John Tzitzikas; Tudor Ciuleanu; Angelos Nikolaou; Panayiotis Pantelakos; Thomas Zaraboukas; Nikolaos Zamboglou; John Daniilidis; Nicolas Ghilezan
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

6.  Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck.

Authors:  Masato Fujii; Mamoru Tsukuda; Bunsuke Satake; Akira Kubota; Akinori Kida; Naoyuki Kohno; Kenji Okami; Yukio Inuyama
Journal:  Int J Clin Oncol       Date:  2004-04       Impact factor: 3.402

Review 7.  PET monitoring of therapy response in head and neck squamous cell carcinoma.

Authors:  Heiko Schöder; Matthew Fury; Nancy Lee; Dennis Kraus
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

8.  Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.

Authors:  Athanassios Argiris; Kerstin M Stenson; Bruce E Brockstein; Bharat B Mittal; Harold Pelzer; Merrill S Kies; Prathima Jayaram; Louis Portugal; Barry L Wenig; Fred R Rosen; Daniel J Haraf; Everett E Vokes
Journal:  Head Neck       Date:  2004-05       Impact factor: 3.147

9.  Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study.

Authors:  Dominic A X Schinagl; Paul N Span; Wim J Oyen; Johannes H A M Kaanders
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-02       Impact factor: 9.236

10.  Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Authors:  H Katori; M Tsukuda; I Mochimatu; J Ishitoya; S Kawai; Y Mikami; H Matsuda; Y Tanigaki; C Horiuchi; Y Ikeda; T Taguchi; M Ono; T Yoshida; S Hirose; Y Sakuma; K Yamamoto
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

View more
  2 in total

1.  Imaging strategy for response evaluation to chemoradiotherapy of the nodal disease in patients with head and neck squamous cell carcinoma.

Authors:  Goshi Nishimura; Kenichiro Yabuki; Masaharu Hata; Masanori Komatsu; Takahide Taguchi; Masahiro Takahashi; Osamu Shiono; Daisuke Sano; Yasuhiro Arai; Hideaki Takahashi; Yoshihiro Chiba; Nobuhiko Oridate
Journal:  Int J Clin Oncol       Date:  2015-12-28       Impact factor: 3.402

2.  [18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis.

Authors:  Aurélien Justet; Astrid Laurent-Bellue; Gabriel Thabut; Arnaud Dieudonné; Marie-Pierre Debray; Raphael Borie; Michel Aubier; Rachida Lebtahi; Bruno Crestani
Journal:  Respir Res       Date:  2017-04-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.